Literature DB >> 7545759

Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet.

Y Wang1, J G Corr, H T Thaler, Y Tao, W R Fair, W D Heston.   

Abstract

BACKGROUND: Geographic variation in the incidence of clinically detected prostate cancer is considerable, with a 120-fold greater incidence in the United States than in China. The incidence of latent prostate cancer, however, shows little variation worldwide, with approximately 30% of men older than age 50 years having microfocal disease (determined by autopsy). Some epidemiologic studies have suggested that a high intake of dietary fat may constitute a risk factor for the development of advanced prostate cancer.
PURPOSE: We studied the influence of dietary fat content on the growth of tumors established in athymic nude mice with androgen-sensitive, human prostatic adenocarcinoma cells (LNCaP cells). We also investigated whether manipulation of dietary fat content altered prostate-specific antigen (PSA) production by these tumors.
METHODS: Tumors were induced in nude mice by subcutaneous injection of 10(6) LNCaP cells. Both the American Type Culture Collection (ATCC) LNCaP cell line and a more androgen-responsive subline derived from it (i.e., the Harris LNCaP cell line) were used. Mice were fed a 40.5-kcal% fat diet at the time of tumor cell injection. Three weeks later, after measurable tumors were formed, the animals were assigned to receive diets with one of the following fat contents: 40.5, 30.8, 21.2, 11.6, or 2.3 kcal% fat. Food intake, animal weights, and tumor volumes were recorded weekly; serum PSA and testosterone levels were measured at the termination of the study. Post hoc multiple comparisons were made using the Student-Newman-Keuls procedure. Two-sided tests of statistical significance were used to evaluate pairwise comparisons.
RESULTS: Tumor growth rates, final tumor weights, and ratios of final tumor weights to animal weights were substantially greater in groups that continued to receive a 40.5-kcal% fat diet than in groups whose diets were changed to 2.3 kcal%, 11.6 kcal%, or 21.2 kcal% fat (all P values < .04). Comparison of these parameters among the 2.3-kcal%, 11.6-kcal%, and 21.2-kcal% dietary fat groups did not reveal any statistically significant differences. No statistically significant differences were noted in total ingested calories, animal weight gain, serum testosterone levels, or histopathologic characteristics of the tumors among the tested dietary groups. Serum PSA levels were highest in the 40.5-kcal% fat group and lowest in the 2.3-kcal% fat group (evaluated only for ATCC LNCaP cells; P < .05).
CONCLUSIONS: Reduction of dietary fat substantially slows the growth of tumors established from human prostatic adenocarcinoma cells in a murine xenograft model. A positive association persists between tumor volumes and serum PSA levels even after extreme modification of dietary fat content.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545759     DOI: 10.1093/jnci/87.19.1456

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  45 in total

1.  Life cycle of the African-American male: improving survival outcomes.

Authors:  G C Dennis
Journal:  J Natl Med Assoc       Date:  1999-01       Impact factor: 1.798

2.  MR T1 and T2 relaxations in cysts and abscesses measured by 1.5 T MRI.

Authors:  U N Yilmaz; F Yaman; S S Atilgan
Journal:  Dentomaxillofac Radiol       Date:  2012-07       Impact factor: 2.419

Review 3.  Diet and prostate cancer: mechanisms of action and implications for chemoprevention.

Authors:  Vasundara Venkateswaran; Laurence H Klotz
Journal:  Nat Rev Urol       Date:  2010-07-20       Impact factor: 14.432

4.  Will metformin postpone high-fat diet promotion of TRAMP mouse prostate cancer development and progression?

Authors:  Hua Xu; Meng-Bo Hu; Pei-de Bai; Wen-Hui Zhu; Qiang Ding; Hao-Wen Jiang
Journal:  Int Urol Nephrol       Date:  2014-08-27       Impact factor: 2.370

5.  Effect of isocaloric low fat diet on prostate cancer xenograft progression in a hormone deprivation model.

Authors:  Jessica C Lloyd; Jodi A Antonelli; Tameika E Phillips; Elizabeth M Masko; Jean-Alfred Thomas; Susan H M Poulton; Michael Pollak; Michael Pollack; Stephen J Freedland
Journal:  J Urol       Date:  2010-02-20       Impact factor: 7.450

6.  Complementary medicine for prostate cancer: effects of soy and fat consumption.

Authors:  M A Moyad; W A Sakr; D Hirano; G J Miller
Journal:  Rev Urol       Date:  2001

7.  Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.

Authors:  Paula Vainio; Santosh Gupta; Kirsi Ketola; Tuomas Mirtti; John-Patrick Mpindi; Pekka Kohonen; Vidal Fey; Merja Perälä; Frank Smit; Gerald Verhaegh; Jack Schalken; Kalle A Alanen; Olli Kallioniemi; Kristiina Iljin
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 8.  Risk factors for prostate cancer.

Authors:  Amit R Patel; Eric A Klein
Journal:  Nat Clin Pract Urol       Date:  2009-02

9.  The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model.

Authors:  Jorge Caso; Elizabeth M Masko; Jean A Thomas Ii; Susan H Poulton; Mark Dewhirst; Salvatore V Pizzo; Stephen J Freedland
Journal:  Prostate       Date:  2012-10-04       Impact factor: 4.104

10.  Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis.

Authors:  Stephen J Freedland; John Mavropoulos; Amy Wang; Medha Darshan; Wendy Demark-Wahnefried; William J Aronson; Pinchas Cohen; David Hwang; Bercedis Peterson; Timothy Fields; Salvatore V Pizzo; William B Isaacs
Journal:  Prostate       Date:  2008-01-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.